Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Tumor immunology

COMPLEMENTing immunotherapy

Nature Cancer volume 3, pages 1144–1146 (2022)Cite this article

Subjects

Intratumoral activation of the complement cascade may have therapeutic potential in patients with lung cancer with strong EGFR signaling, shows a new study. EGFR-triggered expression of CD55 and CD59 prevents opsonization of tumor cells, inhibits antitumor immunity and confers resistance to immune-checkpoint inhibitors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Complement and cancer immunotherapy.

References

  1. Shao, F. et al. Nat. Cancer https://doi.org/10.1038/s43018-022-00444-4 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Roumenina, L. T., Daugan, M. V., Petitprez, F., Sautes-Fridman, C. & Fridman, W. H. Nat. Rev. Cancer 19, 698–715 (2019).

    Article  CAS  Google Scholar 

  3. Hsu, Y. F. et al. Mol. Cancer 9, 139 (2010).

    Article  Google Scholar 

  4. Patil, N. S. et al. Cancer Cell 40, 289–300 e4 (2022).

    Article  CAS  Google Scholar 

  5. Meylan, M. et al. Immunity 55, 527–541 e5 (2022).

    Article  CAS  Google Scholar 

  6. Ajona, D. et al. J. Natl Cancer Inst. 105, 1385–1393 (2013).

    Article  CAS  Google Scholar 

  7. Kwak, J. W. et al. Cancer Res. 78, 143–156 (2018).

    Article  CAS  Google Scholar 

  8. Ajona, D. et al. Cancer Discov. 7, 694–703 (2017).

    Article  CAS  Google Scholar 

  9. Midha, A., Dearden, S. & McCormack, R. Am. J. Cancer Res. 5, 2892–2911 (2015).

    PubMed  PubMed Central  Google Scholar 

  10. To, K. K. W., Fong, W. & Cho, W. C. S. Front. Oncol. 11, 635007 (2021).

    Article  Google Scholar 

  11. Madeddu, C. et al. Int. J. Mol. Sci. 23, 6489 (2022).

    Article  CAS  Google Scholar 

  12. Daugan, M. V. et al. Cancer Immunol. Res. 9, 909–925 (2021).

    Article  CAS  Google Scholar 

  13. Golec, E. et al. Proc. Natl Acad. Sci. USA 119, e2120083119 (2022).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris Cité, Paris, France

    Lubka T. Roumenina & Isabelle Cremer

Authors
  1. Lubka T. Roumenina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabelle Cremer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lubka T. Roumenina.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roumenina, L.T., Cremer, I. COMPLEMENTing immunotherapy. Nat Cancer 3, 1144–1146 (2022). https://doi.org/10.1038/s43018-022-00442-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-022-00442-6

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer